Received: from nobody by stodi.digitalkingdom.org with local (Exim 4.76) (envelope-from ) id 1UKNiZ-0000ZZ-09 for lojban-newreal@lojban.org; Mon, 25 Mar 2013 23:50:47 -0700 Received: from howdynews24.com ([67.214.188.186]:39121) by stodi.digitalkingdom.org with esmtp (Exim 4.76) (envelope-from ) id 1UKNiT-0000Ys-Op for lojban@lojban.org; Mon, 25 Mar 2013 23:50:46 -0700 DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=mg6; d=morouldi.info; h=To:Subject:Message-ID:Date:From:Reply-To:MIME-Version:List-Unsubscribe:Content-Type:Content-Transfer-Encoding; i=ginstay@morouldi.info; bh=2sH99LsHiTLPt+71RVO+Wb7adxw=; b=XYQLRO91f6jjpzF1PYi35mUu7uvxO5t+GSxyh/IFPZALcBnsndIYTGSUIXtVC6u0VwDEE+5E/hJT oZS15+t6oUZzrTvGNhwGNkq122FBBBHh46kzWw7BMYgVVIcV24AMQ/cfEZ66lYeEOUyy22fz6J7a lvKxi3jk4w3yq76H7Hg= DomainKey-Signature: a=rsa-sha1; c=nofws; q=dns; s=mg6; d=morouldi.info; b=b/K6+xh7aNgy9VGrDFBVJirzvzB1qNqlgMb++Fj75WsAz35739B6xdERKtkgASjqBBTf2GpqfqRe V7ebFYLKoVT1jK+AEFEchm+zWRyYanE3dh6VYcCh3hSfUKBkNXff62pLtyBO9OyGw46J9MPxIA5s irhfJhaltdgEH2P3O0A=; To: lojban@lojban.org Subject: Possible Future Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Worthwhile Message-ID: Date: Tue, 26 Mar 2013 00:50:07 -0600 From: "InvestWise" Reply-To: ginstay@morouldi.info MIME-Version: 1.0 X-Mailer-LID: 72 List-Unsubscribe: X-Mailer-RecptId: 29646973 X-Mailer-SID: 151 X-Mailer-Sent-By: 1 Content-Type: multipart/alternative; charset="UTF-8"; boundary="b1_d0cfc0e0ebb7e2987e15607e97f50f7b" Content-Transfer-Encoding: 8bit X-Spam-Score: 2.9 (++) X-Spam_score: 2.9 X-Spam_score_int: 29 X-Spam_bar: ++ X-Spam-Report: Spam detection software, running on the system "stodi.digitalkingdom.org", has identified this incoming email as possible spam. The original message has been attached to this so you can view it (if it isn't spam) or label similar future email. If you have any questions, see the administrator of that system for details. Content preview: Probable Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Worthwhile As Nuvilex, Inc. (OTCQB: NVLX) meticulously arranges for its Phase III pancreatic cancer trials, the approximately $30-million it has invested in its exclusive and proprietary living cell encapsulation or “Cell-in-a-Box” technology could be money well spent considering the return in yearly sales that cancer medications generate in the marketplace. [...] Content analysis details: (2.9 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 2.7 RCVD_IN_PSBL RBL: Received via a relay in PSBL [67.214.188.186 listed in psbl.surriel.com] -0.0 SPF_HELO_PASS SPF: HELO matches SPF record -0.0 SPF_PASS SPF: sender matches SPF record 0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked. See http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block for more information. [URIs: morouldi.info] 0.3 URIBL_RHS_DOB Contains an URI of a new domain (Day Old Bread) [URIs: morouldi.info] 0.0 HTML_MESSAGE BODY: HTML included in message -0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's domain 0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid -0.1 DKIM_VALID Message has at least one valid DKIM or DK signature --b1_d0cfc0e0ebb7e2987e15607e97f50f7b Content-Type: text/plain; format=flowed; charset="UTF-8" Content-Transfer-Encoding: 8bit Probable Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Worthwhile As Nuvilex, Inc. (OTCQB: NVLX) meticulously arranges for its Phase III pancreatic cancer trials, the approximately $30-million it has invested in its exclusive and proprietary living cell encapsulation or “Cell-in-a-Box” technology could be money well spent considering the return in yearly sales that cancer medications generate in the marketplace. The first type the company is choosing to confront is advanced pancreatic cancer – a market that Eli Lilly’s medication Gemzar has conquered and brings in about $1.4-billion yearly. Nuvilex has about $25-million invested in two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer using the blend of the widely-used anticancer medication, ifosfamide, and encapsulated cells capable of adapting the ifosfamide, into its “cancer-killing” form as well as for preclinical studies researching the potential use of the cell encapsulation technology in the development of treatments for other cancers and other diseases. Furthermore, the company has invested almost an additional $2-million into furthering the development of the “Cell-in-a-Box” technology. This is a pretty substantial price tag for such a small biotech, but with the outcomes the company has seen in its two clinical trials, the future looks very encouraging. In those trials, the outcomes are outpacing the current gold standard, the aforementioned Eli Lilly’s medicine Gemzar. Cancer medications are big business, and those medications are even bigger business when they work, and when they lengthen lives, and so far, Nuvilex’s cell encapsulation technology has shown it does work and it does lengthen lives. A quick scan at the major outcomes in those two trials demonstrate that with twenty-seven patients included, a ample response was noticeable in that the use of the living cell encapsulation-ifosfamide grouping helped patients to a better outcome than that previously reported with standard single-medication (Gemzar) therapy. Outcomes from these trials included; average survival time and one-year survival rate were almost doubled as equated to historical data for Gemzar. The gravity of ifosfamide's side effects was lessened because only one-third of its normal dose was used. No harm to tissues surrounding the capsules was recorded. Cells within the capsules were protected from harm by the patients’ immune systems. Cells within the capsules were alive and functioning – even after more than two years. And, this is only the treatment for advanced pancreatic cancer which is as grave a disease as it gets – how about using this technology as a treatment for other types of cancer? Nuvilex’s “Cell-in-a-Box” technology could make its mark perfecting on the industry standard in one type of cancer after the other, and when you start to ponder the billions being made each year in those medicines, that surely makes the technology well worth the investment to date. To stop receiving these emails:http://morouldi.info/unsubscribe.php?M=29646973&C=dfde2e12c02c5d5f2da491323a930c2f&L=72&N=151 View disclaimer http://morouldi.info/link.php?M=29646973&N=151&L=3&F=T 10200 Forest Green BLVD, STE 112, Louisville, KY 40223 U.S.A. --b1_d0cfc0e0ebb7e2987e15607e97f50f7b Content-Type: text/html; charset="UTF-8" Content-Transfer-Encoding: 8bit

Possible Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Make Investment in Technology Sensible

As Nuvilex, Inc. (OTCQB: NVLX) persistently primes for its Phase III pancreatic cancer trials, the nearly $30-million it has invested in its exclusive and proprietary living cell encapsulation or “Cell-in-a-Box” technology could be funds well invested given the profit in annual sales that cancer medications beget in the marketplace.

The first kind the company is choosing to confront is advanced pancreatic cancer – a market that Eli Lilly’s medication Gemzar has dominated and nets about $1.4-billion yearly.

Nuvilex has about $25-million invested in two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer using the combination of the widely-used anticancer medication, ifosfamide, and encapsulated cells capable of altering the ifosfamide, into its “cancer-killing” form as well as for preclinical studies exploring the potential use of the cell encapsulation technology in the advancement of treatments for other cancers and other diseases. Furthermore, the company has earmarked almost an additional $2-million into expanding the development of the “Cell-in-a-Box” technology.

This is a pretty substantial price tag for such a small biotech, but with the outcomes the company has seen in its two clinical trials, the future looks very bright. In those trials, the outcomes are surpassing the current gold standard, the aforementioned Eli Lilly’s medicine Gemzar.

Cancer medications are big business, and those medications are even bigger business when they are successful, and when they extend lives, and so far, Nuvilex’s cell encapsulation technology has shown it does work and it does extend lives.

A quick scan at the momentous outcomes in those two trials shows that with twenty-seven patients included, a significant response was recorded in that the use of the living cell encapsulation-ifosfamide grouping helped patients to a better outcome than that formerly reported with standard single-medication (Gemzar) therapy.

Outcomes from these trials included; average survival time and one-year survival rate were almost doubled as equated to historical data for Gemzar. The gravity of ifosfamide's side effects was decreased because only one-third of its typical dose was used. No harm to tissues surrounding the capsules was recorded. Cells within the capsules were protected from harm by the patients’ immune systems. Cells within the capsules were thriving and functioning – even after more than two years.

And, this is only the treatment for advanced pancreatic cancer which is as ruthless a disease as you can find – what about using this technology as a treatment for other types of cancer? Nuvilex’s “Cell-in-a-Box” technology could make its mark enhancing on the industry standard in one kind of cancer after the other, and when you start to contemplate the billions being generated each year in those medicines, that undoubtedly makes the technology well worth the investment to date.

Unsubscribe | Disclaimer

10200 Forest Green Blvd, Ste. 112, Louisville, Kentucky 40223 United States

--b1_d0cfc0e0ebb7e2987e15607e97f50f7b--